Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.
Nathan den BroederLise VerhoefYaël A de ManMarc-Redwart KokRogier ThurlingsWilfred van der WeeleBart Jf van den BemtFrank Hj van den HoogenAatke van der MaasAlfons A den BroederPublished in: RMD open (2024)
Long-term use of ultralow doses of RTX is effective in patients with rheumatoid arthritis responding to standard dose RTX.